Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease

被引：0

作者：

Anastasia Kontana ^{[1
]}

Konstantinos Tziomalos ^{[1
]}

机构：

[1] First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital

来源：

World Journal of Gastroenterology | 2019年 / 28期

关键词：

Nonalcoholic fatty liver disease; Type 2 diabetes mellitus; Sodium-glucose co-transporter-2 inhibitors; Steatosis; Fibrosis; Transaminases;

D O I：

暂无

中图分类号：

R575.5 [肝代谢障碍];

学科分类号：

1002 ; 100201 ;

摘要：

Nonalcoholic fatty liver disease(NAFLD) is the most prevalent cause of chronic liver disease worldwide. NAFLD is considerably more frequent in patients with type 2 diabetes mellitus(T2 DM) than in the general population and is also more severe histologically in this group. Sodium-glucose co-transporter-2(SGLT2)inhibitors, the newest class of antidiabetic agents, appear to represent a promising option for the management of NAFLD in patients with T2 DM. In a number of studies, treatment with SGLT2 inhibitors resulted in a reduction in hepatic steatosis and in transaminase levels. However, existing studies are small,their follow-up period was short and none evaluated the effects of SGLT2 inhibitors on liver histology. Accordingly, larger studies are needed to verify these preliminary results and define the role of SGLT2 inhibitors in the treatment of NAFLD in patients with T2 DM.

引用

页码：3664 / 3668

页数：5

共 12 条

[1]

Pharmacokinetics of Single-Dose Ertugliflozin in Patients With Hepatic Impairment[J] . Vaishali Sahasrabudhe,Steven G. Terra,Anne Hickman,Didier Saur,Sangeeta Raje,Haihong Shi,Kyle Matschke,Susan Zhou,David L. Cutler.Clinical Therapeutics . 2018

[2]

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)[J] . Mohammad Shafi Kuchay,Sonal Krishan,Sunil Kumar Mishra,Khalid Jamal Farooqui,Manish Kumar Singh,Jasjeet Singh Wasir,Beena Bansal,Parjeet Kaur,Ganesh Jevalikar,Harmendeep Kaur Gill,Narendra Singh Choudhary,Ambrish Mithal.Diabetes Care . 2018 (8)

[3]

Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial[J] . Daisuke Ito,Satoshi Shimizu,Kazuyuki Inoue,Daigo Saito,Morifumi Yanagisawa,Kouichi Inukai,Yuji Akiyama,Yoshihiro Morimoto,Mitsuhiko Noda,Akira Shimada.Diabetes Care . 2017 (10)

[4]

Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study[J] . Hiroshi Tobita,Shuichi Sato,Tatsuya Miyake,Shunji Ishihara,Yoshikazu Kinoshita.Current Therapeutic Research . 2017

[5]

Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport[J] . Mudaliar Sunder,Polidori David,Zambrowicz Brian,Henry Robert R..Diabetes Care . 2015 (12)

[6]

Effect of Hepatic or Renal Impairment on the Pharmacokinetics of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor[J] . Damayanthi Devineni,Christopher R. Curtin,Thomas C. Marbury,William Smith,Nicole Vaccaro,David Wexler,An Vandebosch,Sarah Rusch,Hans Stieltjes,Ewa Wajs.Clinical Therapeutics . 2015 (3)

[7] Cardiometabolic Effects of a New Class of Antidiabetic Agents [J].

Desouza, Cyrus V. ;

Gupta, Namita ;

Patel, Anery .

CLINICAL THERAPEUTICS, 2015, 37 (06) :1178-1194

[8]

Non-alcoholic fatty liver disease: A precursor of the metabolic syndrome[J] . Amedeo Lonardo,Stefano Ballestri,Giulio Marchesini,Paul Angulo,Paola Loria.Digestive and Liver Disease . 2014

[9]

Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment[J] . S. Macha,P. Rose,M. Mattheus,R. Cinca,S. Pinnetti,U. C. Broedl,H. J. Woerle.Diabetes Obes Metab . 2014 (2)

[10]

The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study[J] . Leon A. Adams,James F. Lymp,Jenny St. Sauver,Schuyler O. Sanderson,Keith D. Lindor,Ariel Feldstein,Paul Angulo.Gastroenterology . 2005 (1)

← 1 2 →